Low-Molecular-Weight HPMC Nicotinamide Composition for Lower-Gut Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional nicotinamide formulations fail to effectively deliver the substance to the lower small intestine and colon, leading to insufficient exposure and systemic availability, necessitating improved extended-release and/or sustained-release formulations with a focus on systemic and topical delivery.
Innovation Solution
Compositions comprising low-molecular-weight HPMC and/or HPC are formulated for oral administration, providing at least partially extended and/or sustained and/or controlled release of nicotinamide, with specific molecular weights for HPMC ≤85 kDa and HPC ≤90 kDa, enabling targeted release in the stomach, small intestine, and colon.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional nicotinamide formulations are used, then immediate release occurs in the upper gastrointestinal tract, but the lower small intestine and colon are insufficiently exposed to nicotinamide
Solution Approach 1:
The patent changes the molecular weight parameter of HPMC from conventional high molecular weight to low molecular weight (≤85 kDa), which fundamentally alters the release characteristics of nicotinamide. This parameter change enables the formulation to achieve both reliable delivery to the lower gastrointestinal tract and adequate systemic availability simultaneously
Solution Approach 2:
The patent creates a composite formulation system combining low-molecular-weight HPMC with nicotinamide, where the specific polymer-substance interaction produces unique release properties that neither component achieves alone, resolving the contradiction between targeted delivery and systemic availability
2Duration of action of moving object
If extended-release formulations are developed to prolong nicotinamide release, then duration of action is improved, but manufacturing complexity increases
Solution Approach 1:
By changing the molecular weight parameter of HPMC to low molecular weight (≤85 kDa), the patent achieves extended release functionality with a simpler formulation approach, avoiding the need for complex multi-layer structures or sophisticated release mechanisms that would otherwise be required
Solution Approach 2:
The patent uses a simple, well-established polymer (HPMC) with modified molecular weight characteristics to achieve extended release, rather than employing complex, expensive, or novel materials that would increase manufacturing complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions achieve a reliable and varied release pattern of nicotinamide, ensuring higher trough levels and continuous systemic exposure, while also benefiting the intestinal mucosa and microbiota through topical delivery.
Implementation Method 1
the highly water soluble nicotinamide is rapidly taken up by the gastrointestinal mucosa without the need for specific transporters
Implementation Method 2
improved extended-release and/or sustained-release and/or controlled-release formulations comprising nicotinamide
Data Source
AI summary
A composition comprising nicotinamide and low-molecular-weight HPMC and/or HPC, characterized in that the composition is formulated for oral administration with at least partially extended and/or sustained and/or controlled release of nicotinamide.